Alzamend Neuro (ALZN) Q4 2025 earnings summary

Executive summary

• Achieved significant improvement in financial position with increased cash and equity year-over-year.

• Completed $5 million private placement financing months ahead of schedule, supporting ongoing clinical programs.

• Advanced clinical pipeline with five Phase II trials for AL001 and continued development of ALZN002.

Financial highlights

• Net cash provided by financing activities was $10.4 million for the year ended April 30, 2025.

• Stockholder equity rose to $3.9 million at April 30, 2025, from a deficit of $2.6 million a year earlier.

• Cash increased to $3.9 million at April 30, 2025, from $0.4 million at April 30, 2024.

• Total liabilities decreased to $0.6 million at April 30, 2025, from $3.2 million at April 30, 2024.

Outlook and guidance

• Topline results from the first AL001 Phase II trial expected by year-end 2025, with additional trials launching through early 2026.

• Anticipates further proceeds if warrants from recent financing are exercised.